The nonalcoholic steatohepatitis (NASH) market is set to reach USD 9.84 billion in 2025, driven by the increasing prevalence of obesity, type 2 diabetes, and metabolic disorders. As demand for novel therapeutics, fibrosis-targeting drugs, and noninvasive diagnostic tools rises, the market is projected to surge to USD 52.23 billion by 2033, with a CAGR of 23.20%. This episode explores breakthroughs in NASH treatment, drug development, and liver disease management shaping the future of hepatology.